The listing of claims will replace all prior versions, and listings, of claims in the application: Listing of Claims:

1. (Currently Amended) The use of a compound of a A compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity for use in human or veterinary medicine:

$$R_1$$
 A
 R_3
 A
 (I)

wherein

ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms;

R₁ is attached to a first ring atom of ring A and is a group of formula (IA):

$$-Ar^{1}-(Alk^{1})_{p}-(Z)_{r}-(Alk^{2})_{s}-Q$$
 (IA)

wherein in any compatible combination

Ar¹ is an optionally substituted aryl or heteroaryl radical,

Alk¹ and Alk² are optionally substituted divalent C₁-C₆ alkylene or C₂-C₆ alkenylene radicals,

p, r and s are independently 0 or 1,

Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;

R₂ is attached to a second ring atom of ring A, which is adjacent the first ring atom to which

 R_1 is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a neighbouring neighboring ring atom, and if not absent R_1 is hydrogen or

- (i) a group of formula (IA) as defined in relation to R₁; .
- (ii) a carboxamide radical; or
- (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula $(Alk^1)_p$ - $(Z)_r(Alk^2)_s$ -Q wherein Q, Alk^1 , Alk^2 , Z, p, r and s are as defined above in relation to group (IA); and

 R_3 is attached to a third ring atom of ring A, which is adjacent the second ring atom to which R_2 is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a neighbouring neighboring ring atom, and if not absent R_2 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C_1 - C_6 alkyl, C_4 - C_6 C_2 - C_6 alkenyl, or C_4 - C_6 C_2 - C_6 alkynyl; or a carboxyl, carboxamide or carboxyl ester group,

PROVI DED THAT (a) at least one of R₂ and R₃ is present and is other than hydrogen and (b) the compound of formula (I) is not one of formula (IA) (IB), (IC) or (ID)

wherein R_1 , R_2 and R_3 are as defined above, and R is is-hydrogen or optionally substituted C_1 - C_6 alkyl.

- 2. (Currently Amended) The <u>use-compound</u> as claimed in claim 1 wherein the group the ring A is aromatic.
- 3. (Currently Amended) The <u>use-compound</u> as claimed in claim 1 or elaim 2 wherein both R_1 and R_2 are attached to ring carbon atoms.
- 4. (Currently Amended) The <u>use-compound</u> as claimed in claim 1 or claim 2 wherein one of R_1 and R_2 is attached to a ring carbon atom and the other to a ring nitrogen atom.
- 5. (Currently Amended) The <u>use-compound</u> as claimed in claim 1 wherein the ring A is a 1, 2, 4-tetrazolyl ring or a 1, 2, 3-triazole ring.
- 6. (Currently Amended) The <u>use-compound</u> as claimed in claim 1 wherein the compound of formula (I) has formula (IE) or (IF)

wherein R1, R2, and R3-R1, R2, and R3 are as defined in claim 1.

7. (Currently Amended) The <u>use-compound</u> as claimed in <u>any of the preceding claims-claim</u>

<u>1</u> wherein in the compound of formula (I) R₁ has formula (II):

$$Q-(Alk^2)_s-(Z)_r-(Alk^1)_p$$

$$OH$$
(II)

wherein Alk^1 , Alk^2 , p, r, s, Z and Q are as defined above in relation to R_1 , and R represents one or more optional substituents.

- 8. (Currently Amended) The <u>use-compound</u> as claimed in <u>any of the preceding claims-claim</u>

 1 wherein in the group R₁ of the compound of formula (I) each of p, r and s is 0, and Q is hydrogen.
- 9. (Currently Amended) The <u>use-compound</u> as claimed in claim 8 wherein R₁ is 2-hydroxyphenyl optionally further substituted by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy, chloro, or bromo.
- 10. (Currently Amended) The <u>use-compound</u> as claimed in any of claims 1 to 8 claim 1 wherein in the compound of formula (I) R₁ has formula ((IIA):

wherein R represents bromo, chloro, phenyl, C₁-C₆ alkyl or phenyl(C₁-C₆ alkyl)-.

11. (Currently Amended) The <u>use-compound</u> as claimed in <u>any of claims 1 to 7 claim 1</u> wherein in the group R_1 of the compound of formula (I) one or more of p, r and s is 1.

- 12. (Currently Amended) The <u>use-compound</u> as claimed in claim 11 wherein p and/or s is/are 1 and r is 0.
- 13. (Currently Amended) The <u>use-compound</u> as claimed in claim 11 wherein each of p, r, and s is 1.
- 14. (Currently Amended) The <u>use-compound</u> as claimed in claim 11 wherein p and s are 0 and r is 1.
- 15. (Currently Amended) The <u>use-compound</u> as claimed in <u>any of the preceding claims claim</u> <u>1</u> wherein R₂ is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.
- 16. (Currently Amended) The <u>use-compound</u> as claimed in <u>any of claims 1 to 14-claim 1</u> wherein R₂ is optionally substituted phenyl.
- 17. (Currently Amended) The <u>use compound</u> as claimed in <u>any of claims 1 to 14 claim 1</u> wherein R_2 is a carboxamide radical of formula -CONR^B(Alk)_nR^A wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical, n is 0 or 1,

R^B is hydrogen or a C₁-C₆ alkyl or C₂-C₆ alkenyl group,

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms

selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

18. (Currently Amended) The use compound as claimed claim 17 wherein

Alk is an optionally substituted –CH₂-, -CH₂CH₂-, -CH₂CH₂-, CH₂CH₂-, CH₂CH=CH-, or – CH₂CCCH₂- radical.

n is 0 or 1,

R^B is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

R^A is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4 methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or Nmorpholinyl,

or R^A and R^B taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.

- 19. (Currently Amended) The <u>use-compound</u> as claimed in claim 17 wherein n is 0, R^B is hydrogen and R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.
- 20. (Currently Amended) The <u>use-compound</u> as claimed in <u>any of the preceding claims-claim</u> <u>1</u> wherein R₃ is hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, or hydroxyethyl.
- 21. (Currently Amended) The <u>use-compound</u> as claimed in <u>any of claims 1-to 19-claim 1</u> wherein R_3 is a carboxamide group -CONR^B(Alk)_nR^A-as defined in any of claims 16 to 18 in relation to R_2 wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical, n is 0 or 1,

R^B is hydrogen or a C₁-C₆ alkyl or C₂-C₆ alkenyl group,

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.

or R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

- 22. (Currently Amended) A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (I) as defined in any of claims 1 to 21 claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.
- 23. (Currently Amended) The use as claimed in any of claims 1 to 21 or a method as claimed claim 21 for immunosuppression or the treatment of cancer; viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.

24. (Canceled)

25. Currently Amended) A pharmaceutical or veterinary composition comprising a compound as defined in any of claims 1 to 21 claim 1, or a salt hydrate or solvate thereof, together with a pharmaceutically or veterinarily acceptable carrier.